Pharmacotherapeutic considerations for elderly patients with colorectal cancer

Rogers, Jane E.; Eng, Cathy

doi:10.1080/14656566.2019.1657826

Cited by 4 publications

(5 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRC is the third most common cancer diagnosed between both sexes with an estimated death rate of 51,020 and an estimated 145,600 new cases for 2019 [ 11 ]. Metastatic CRC (mCRC) is an advanced age malignancy that presents at a median age of 67 years [ 12 ]. In our study, the mean age of diagnosis of mCRC was 60.13 ± 12.52 years, younger than in the literature.…”

Section: Discussionmentioning

confidence: 99%

Contribution of “complete response to treatment” to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis

Bulut¹,

Oytun

Almuradova

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

Background The aim of the study is to reveal the contribution of complete response (CR) to treatment to overall survival (OS) in patients with unresectable metastatic colorectal cancer. In addition, to evaluate progression-free survival (PFS) in patients who attained CR to treatment and to examine the clinicopathologic features of the patient group with CR. Methods This article is a retrospective chart review. Patients diagnosed with metastatic colorectal cancer were divided into two groups. The systemic treatment was compared with the patients who received a full response according to the Response Evaluation Criteria in Solid Tumors (RECIST1.1) and those who did not attain CR (progression partial response and stable response) in terms of both PFS and OS data, and the effect of attaining CR to treatment on prognosis was evaluated. Results A total of 222 patients were included in the study. 202 of 222 patients could be evaluated in terms of complete response. All data from their files were tabulated and analyzed retrospectively. The mean age of diagnosis of the study group was 60.13 ± 12.52 years. The total number of patients who attained CR to treatment was 31 (15.3%); 171 (84.6%) patients did not attain CR. Patients who had a CR had longer median PFS times than patients who did not have a CR (15.2 vs. 7.4 months, P<0.001). Patients who had CR had longer median survival times than patients who did not have a CR (39.2 vs. 16.9 months, P<0.001). In subgroup patients who underwent primary surgery, the number of patients who attained CR was statistically higher compared with the number of patients who did not attain CR (p<0.001). Complete response was less common in the presence of liver metastasis and bone metastasis (p = 0.041 and p = 0.046, respectively), had a negative prognostic effect. In other words, 89.1% of patients with liver metastasis, 100.0% of patients with bone metastasis, and 88.7% of those who died did not have a CR to the treatment. According to multivariate analysis, CR to treatment, primary surgery, first-line chemotherapy (combination compared with fluoropyrimidine), and no bone metastasis were found to be predictors for OS. Conclusion Providing CR with systemic treatment in patients with unresectable metastatic colorectal cancer (mCRC) contributes to prognosis. The primary resection in our secondary acquisitions from the study, the number of metastatic regions and the combination therapy regimens also contributed to the prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Contribution of “complete response to treatment” to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis

Bulut¹,

Oytun

Almuradova

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Most GI malignancies are diagnosed in the elderly and carry age-related risks with medications. 4,[7][8][9][10][11][12][13] Older patients may be affected by metabolism changes, organ dysfunction, and cognitive decline, have multiple comorbidities, take multiple medications, and have changes in functional status. 4,7,[11][12][13] The recent increase in GI malignancies among adolescent and young adult patients poses another challenge, 10 and difficulties in medication adherence have been reported in this population.…”

Section: Introductionmentioning

confidence: 99%

“…4,[7][8][9][10][11][12][13] Older patients may be affected by metabolism changes, organ dysfunction, and cognitive decline, have multiple comorbidities, take multiple medications, and have changes in functional status. 4,7,[11][12][13] The recent increase in GI malignancies among adolescent and young adult patients poses another challenge, 10 and difficulties in medication adherence have been reported in this population. 14 In addition, patients with cancer often choose to supplement their cancer management with complementary medicine, 13,15,16 potentially increasing drug-drug interactions, organ damage, metabolism interference, and additive AEs.…”

Section: Introductionmentioning

confidence: 99%

“…4,7,[11][12][13] The recent increase in GI malignancies among adolescent and young adult patients poses another challenge, 10 and difficulties in medication adherence have been reported in this population. 14 In addition, patients with cancer often choose to supplement their cancer management with complementary medicine, 13,15,16 potentially increasing drug-drug interactions, organ damage, metabolism interference, and additive AEs. Because of these concerns, pharmacist review is of utmost importance.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, patients with cancer often choose to supplement their cancer management with complementary medicine, 13,15,16 potentially increasing drug-drug interactions, organ damage, metabolism interference, and additive AEs. Because of these concerns, pharmacist review is of utmost importance.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Direct Clinical Pharmacist-Patient Telephone Follow-Up: A Focus on GI Medical Oncology Symptom Management

Rogers,

Zadlo,

Leung

et al. 2024

JCO Oncol Pract

Self Cite

View full text Add to dashboard Cite

PURPOSE GI medical oncology care presents unique medication challenges. Here, we captured our clinical pharmacy specialists' (CPSs) involvement in patients with GI cancers starting cycle 1 of a new treatment. METHODS Our quality initiative was performed in three stages (preintervention, intervention, and postintervention). Preintervention: retrospective baseline data collection from May to December 2019. Intervention: one-time telephone encounters were conducted by a CPS between March 15 and June 11, 2021. The primary objective of the quality improvement initiative was to increase patient interaction with a CPS to 80%. Postintervention: data collection to review the impact of CPS telephone encounters. RESULTS Preintervention: we reviewed the electronic health records of 262 patients. Sixty nine percent of patients reported at least one adverse event (AE; range 1-6 AEs) at the first physician follow-up after treatment start. Most reported AEs (78%) were considered modifiable within the scope of CPS practice. Postintervention: during the intervention, 92% of patients (n = 389) received a telehealth encounter with the CPS. At the encounter, 315 patients (81%) reported at least one AE. CPS provided recommendations and/or additional education for 88% of reported AEs. Medication lists required correction 75% of the time. The median time for CPS encounters (including documentation) was 40 minutes. CONCLUSION During a 3-month period, this quality improvement initiative successfully provided an early CPS-based telehealth intervention to identify and make initial recommendations for management of AEs for patients on cycle 1 of systemic therapy for GI cancer.

show abstract

Use of Complementary and Alternative Medicine (CAM) among elderly cancer patients in Korea: A cross-sectional study

Chang,

Im,

Choi

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose As the global population ages, cancer has emerged as a leading cause of death among the elderly. Elderly cancer patients often turn to complementary and alternative medicine (CAM) to manage symptoms and enhance their quality of life. Despite its glowing use, the characteristics and determinants associated with CAM use remain unclear. This study aims to examine the prevalence, types, reasons, and influencing factors of CAM use among elderly cancer patients in Korea. Design This study employed a cross-sectional survey design. Setting/participants This study was conducted at the outpatient clinics of a general hospital in Seoul, Republic of Korea. The participants were elderly cancer patients visiting the outpatient clinics for treatment. Data were collected through face-to-face using a structured questionnaire. Results 60% of all participants reported using CAM. The most common CAM modalities were exercise, particularly fast walking (49.4%), followed by dietary interventions (42.9%). The primary reasons for using CAM were immune enhancement (61.6%), with the main source of information being family members or relatives (42.1%). Having a spouse, a diagnosis of prostate cancer, and having undergone surgical therapy were significantly associated with CAM use. Conclusions This study reveals the significant role of CAM in supportive care for elderly cancer patients in Korea, highlighting exercise, dietary interventions, and immune enhancement as key motivations. The findings underscore the need for comprehensive guidelines integrating CAM into conventional cancer care. Further research is crucial to understand the specific impacts on treatment outcomes, particularly among elderly male cancer patients.

show abstract

Pharmacotherapeutic considerations for elderly patients with colorectal cancer

Cited by 4 publications

References 59 publications

Contribution of “complete response to treatment” to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis

Contribution of “complete response to treatment” to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis

Direct Clinical Pharmacist-Patient Telephone Follow-Up: A Focus on GI Medical Oncology Symptom Management

Use of Complementary and Alternative Medicine (CAM) among elderly cancer patients in Korea: A cross-sectional study

Contact Info

Product

Resources

About